Eli Lilly acquired Adverum, gaining access to Ixo-vec, a gene therapy for wet age-related macular degeneration. Read why I ...

"Eli Lilly buys Adverum in eye disease gene therapy punt" was originally created and published by Pharmaceutical Technology, ...

Please provide the article or its content so I can generate an SEO-friendly meta description based on your guidelines.

Eli Lilly and Company and Adverum Biotechnologies, a clinical-stage gene therapy company aiming to preserve sight for life in ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Under the agreement, Lilly will gain control of Adverum’s lead product candidate, Ixo-vec, a Phase 3 gene therapy designed to ...

Eli Lilly to buy gene therapy developer, Adverum Biotechnologies: Indianapolis Monday, October 27, 2025, 10:00 Hrs [IST] Eli Lilly and Company and Adverum Biotechnologies, Inc., a ...

Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.

Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Eli Lilly's (LLY) deal to ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

Eli Lilly said Friday it is set to acquire clinical-stage company Adverum Biotechnologies for up to $12.47 a share, including milestone payments.